Top > Search of International Patents > DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION

DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION

Foreign code F210010302
File No. (S2019-0497-N0)
Posted date Jan 29, 2021
Country WIPO
International application number 2020JP018512
International publication number WO 2020255574
Date of international filing May 7, 2020
Date of international publication Dec 24, 2020
Priority data
  • P2019-115688 (Jun 21, 2019) JP
Title DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION
Abstract This drug delivery composition is for the delivery of a drug to the spinal cord; comprises a membrane-permeable peptide and a block copolymer in which a polyethylene glycol segment is linked to a hydrophobic polyester segment; and is administered nasally. This pharmaceutical composition comprises the drug delivery composition and a drug for the treatment of a spinal cord disease and is administered nasally for the treatment of a spinal cord disease.
Outline of related art and contending technology BACKGROUND ART
Drug delivery to the spinal cord via systemic circulating blood by oral or intravenous administration is significantly limited by the blood-brain barrier and blood-cerebrospinal fluid barrier, making it difficult to increase the drug concentration in spinal cord tissue to the therapeutic area. In addition, because a large amount of medicament is administered to increase the treatment area, side effects on peripheral tissues may be exhibited via systemic circulation. Intrathecal administration can selectively deliver drugs to spinal cord tissue, but administration planning is difficult because administration requires techniques, is highly invasive, and bears a large burden on a patient.
On the other hand, drug delivery technology has been developed as a technology for delivering drugs to disease sites. g. Methoxypolyethylene glycol (Methoxy Polyethylene Glycol: MPEG) segments and poly (epsilon-caprolactone) (Poly (epsilon-caprolactone): (Patent Document 1) reports a nucleic acid delivery composition containing a block copolymer consisting of PCL) segments and a peptide comprising a liposoluble group consisting of 10 amino acids including arginine and histidine.
Scope of claims (In Japanese)[請求項1]
 薬物を脊髄に送達するための薬物送達用組成物であって、
 ポリエチレングリコールセグメントと疎水性ポリエステルセグメントとが連結したブロックコポリマーと、膜透過性ペプチドと、を含有し、経鼻的に投与される、薬物送達用組成物。

[請求項2]
 前記薬物が、脊髄疾患治療用の薬物である、請求項1に記載の薬物送達用組成物。

[請求項3]
 前記脊髄疾患が、筋萎縮性側索硬化症、脊髄小脳変性症、脊髄性筋萎縮症、原発性側索硬化症、球脊髄性筋萎縮症、慢性疼痛、及び脊髄損傷からなる群より選択される、請求項2に記載の薬物送達用組成物。

[請求項4]
 前記膜透過性ペプチドが、前記疎水性ポリエステルセグメントの末端に結合している、請求項1~3のいずれか一項に記載の薬物送達用組成物。

[請求項5]
 前記膜透過性ペプチドに、直接又は結合基を介して、脂溶性基が結合している、請求項1~3のいずれか一項に記載の薬物送達用組成物。

[請求項6]
 前記脂溶性基が、置換基を有していてもよい炭素数4~30のアルキル基、置換基を有していてもよい炭素数4~30のアルケニル基、及び置換基を有していてもよい炭素数7~30のアラルキル基からなる群より選択される、請求項5に記載の薬物送達用組成物。

[請求項7]
 前記ブロックコポリマーと、前記膜透過性ペプチドとがミセルを形成している、請求項1~6のいずれか一項に記載の薬物送達用組成物。

[請求項8]
 請求項1~7のいずれか一項に記載の薬物送達用組成物と、脊髄疾患治療用の薬物とを含有し、経鼻的に投与される、脊髄疾患を治療するための医薬組成物。

[請求項9]
 前記脊髄疾患が、筋萎縮性側索硬化症、脊髄小脳変性症、脊髄性筋萎縮症、原発性側索硬化症、球脊髄性筋萎縮症、慢性疼痛、及び脊髄損傷からなる群より選択される、請求項8に記載の医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIHON UNIVERSITY
  • SHIZUOKA PREFECTURAL UNIVERSITY CORPORATION
  • Inventor
  • KANAZAWA Takanori
  • KOSUGE Yasuhiro
  • MIYAGISHI Hiroko
  • SUZUKI Naoto
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close